Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation

Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation

Apremilast (Otezla<sup>®</sup>) is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease. While PDE4 inhibition overall is mechanistically understood, the effect of apremi...

Full description

Bibliographic Details
Main Authors: Barbara Meier-Schiesser, Mark Mellett, Marigdalia K. Ramirez-Fort, Julia-Tatjana Maul, Annika Klug, Nicola Winkelbeiner, Gabriele Fenini, Peter Schafer, Emmanuel Contassot, Lars E. French
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:International Journal of Molecular Sciences
Subjects:
PDE4 inhibition
cytokines
inflammasome
Online Access:https://www.mdpi.com/1422-0067/22/23/12878

Internet

https://www.mdpi.com/1422-0067/22/23/12878

Similar Items